SCHEMBL4248199

SCHEMBL4248199

Cn1c(NCCN2CCOCC2)nc2ccc(/C=C3\SC(Nc4c(Cl)cccc4Cl)=NC3=O)cc21

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LCK P06239 9/20 0.43
SMN1; SMN2 Q16637 2/20 0.40
FGFR1 P11362 2/20 0.39
SRC P12931 2/20 0.39
MAPK8 P45983 2/20 0.39
TRPC5 Q9UL62 1/20 0.39
MAPK10 P53779 2/20 0.39
MAPK13 O15264 1/20 0.37
MAPK12 P53778 1/20 0.37
MAPK11 Q15759 1/20 0.37
MAPK14 Q16539 1/20 0.37
ALOX5 P09917 1/20 0.37
TRPV1 Q8NER1 1/20 0.37
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4248201 1.00 LCK (0.43) LCKSMN1; SMN2FGFR1SRCMAPK8
SCHEMBL4238196 0.92 SMN1; SMN2 (0.40) LCKSMN1; SMN2FGFR1SRCMAPK8
SCHEMBL4238199 0.92 SMN1; SMN2 (0.40) LCKSMN1; SMN2FGFR1SRCMAPK8
SCHEMBL4238446 0.88 MAPK1 (0.44) LCKSMN1; SMN2ALOX5ALDH1A1
SCHEMBL4238440 0.88 MAPK1 (0.44) LCKSMN1; SMN2ALOX5ALDH1A1
SCHEMBL4237615 0.84 CSF1R (0.42) MAPK14ALOX5ALDH1A1
SCHEMBL4237618 0.84 CSF1R (0.42) MAPK14ALOX5ALDH1A1
SCHEMBL4242647 0.83 ALOX5 (0.39) LCKSRCMAPK8MAPK10MAPK13
SCHEMBL4242645 0.83 ALOX5 (0.39) LCKSRCMAPK8MAPK10MAPK13
SCHEMBL4242447 0.81 ACVR1 (0.40) LCKSMN1; SMN2FGFR1SRCMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-02-19 US claimed
US-20070249599-A1 Novel Chemical Compounds DUFFY KEVIN J 2007-10-25 US claimed
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-02-19 US disclosed
US-20070249599-A1 Novel Chemical Compounds DUFFY KEVIN J 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249599-A1 Novel Chemical Compounds HIPK3, HIPK1, HIPK4 LCK 2974/4885SMN1; SMN2 2249/4885FGFR1 3347/4885
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS PIK3CA, BTK, PI4KA LCK 76/4885SMN1; SMN2 2523/4885FGFR1 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.